About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Urahplt2
platelet 2
MGI:4836355
Summary 1 genotype
Jump to Allelic Composition Genetic Background Genotype ID
hm1
Urahplt2/Urahplt2 C57BL/6-Urahplt2 MGI:4836356


Genotype
MGI:4836356
hm1
Allelic
Composition
Urahplt2/Urahplt2
Genetic
Background
C57BL/6-Urahplt2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Urahplt2 mutation (0 available); any Urah mutation (13 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body

cellular
• B16.OVA melanoma bearing mice show a greater proportion of proliferating antigen-specific OT-I T cells in both draining and non-draining lymph nodes, before and after Poly I:C treatment compared to wild-type mice indicating increased proliferation of tumor-specific CD8+ T cells

hematopoietic system
• B16.OVA melanoma bearing mice show a greater proportion of proliferating antigen-specific OT-I T cells in both draining and non-draining lymph nodes, before and after Poly I:C treatment compared to wild-type mice indicating increased proliferation of tumor-specific CD8+ T cells
• in the bone marrow and spleen
• an increase in the number of megakaryocytes progenitors in the bone marrow and spleen
• elevated platelet number
• B16.OVA melanoma (expressing a truncated OVA protein) bearing mice that have been adoptively transferred with OVA-specific OT-I T cells show fewer tumor-specific CD8+ T cells in draining lymph node than wild-type mice
• B16 melanoma challenged mice exhibit a smaller increase in NK cell numbers in the tumor-draining lymph node following Poly I:C treatment compared to wild-type mice, but a greater increase in NK cells in tumors

homeostasis/metabolism
• mice exhibit elevated serum uric acid levels
• mice show altered efficacy of the anti-tumor immunotherapy Poly I:C; mice challenged with B16 melanoma and treated with Poly I:C are unable to delay tumor growth as is seen in controls
• however, conventional and monocyte-derived dendritic cells in the tumor-draining lymph nodes and CD8+ T cells in the tumor-draining lymph node and tumor are similarly increased as in controls after Poly I:C immunotherapy and dendritic responses are similar

liver/biliary system
• 54% of mice aged to 2 years had hepatic tumors
• increased THPO secretion

neoplasm
• 54% of mice aged to 2 years had hepatic tumors

immune system
• B16.OVA melanoma bearing mice show a greater proportion of proliferating antigen-specific OT-I T cells in both draining and non-draining lymph nodes, before and after Poly I:C treatment compared to wild-type mice indicating increased proliferation of tumor-specific CD8+ T cells
• B16.OVA melanoma (expressing a truncated OVA protein) bearing mice that have been adoptively transferred with OVA-specific OT-I T cells show fewer tumor-specific CD8+ T cells in draining lymph node than wild-type mice
• B16 melanoma challenged mice exhibit a smaller increase in NK cell numbers in the tumor-draining lymph node following Poly I:C treatment compared to wild-type mice, but a greater increase in NK cells in tumors

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
hyperuricemia DOID:1920 J:267227





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
04/16/2024
MGI 6.23
The Jackson Laboratory